Axonics® to Present at Upcoming Investor Conferences

IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical
technology company focused on the development and commercialization of
novel implantable Sacral Neuromodulation (“SNM”) devices for the
treatment of urinary
and bowel dysfunction, today announced that members of the senior
management team will present at the following upcoming investor
conferences and will be available for meetings with institutional
investors:

• Raymond W. Cohen, Chief Executive Officer, is scheduled to present at
  the Bank of America Merrill Lynch Healthcare Conference on Wednesday,
  May 15, at 10:15 am PDT at the Encore in Las Vegas.
• Cohen is also scheduled to present at the UBS Global Healthcare
  Conference on Wednesday, May 22, at 9:00 am EDT at the Grand Hyatt in
  New York City.

To access the live webcast of the presentations at the aforementioned
conferences, please visit the Events & Presentations page of the
Investors section of the Company’s website at ir.axonicsmodulation.com.
A replay of the webcasts will be available shortly after the conclusion
of the presentations and will be archived on the Company’s website for
90 days.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, CA, is focused on the development and
commercialization of a novel implantable SNM system for patients with
urinary and bowel dysfunction. The Axonics r-SNM® System is the first
rechargeable Sacral Neuromodulation system approved for sale
in Europe, Canada and Australia, and the first SNM system to gain CE
mark for full-body MRI conditional labeling. Premarket Approval (PMA)
for the r-SNM System is currently pending with the U.S. FDA. For more
information, visit the Company’s website at www.axonicsmodulation.com.

Contacts

Axonics’ Contact
Axonics Modulation Technologies, Inc.
Dan
Dearen, +1-949-396-6320
President & Chief Financial Officer
ir@axonics.com

Investor
& Media Contact
W2Opure
Matt Clawson, +1-949-370-8500
mclawson@w2ogroup.com